Prosecution Insights
Last updated: July 17, 2026
Application No. 18/505,258

CURABLE COMPOSITION, FILM FORMING METHOD AND ARTICLE MANUFACTURING METHOD

Non-Final OA §103
Filed
Nov 09, 2023
Priority
Jun 09, 2021 — JP 2021-096750 +2 more
Examiner
GRAHAM, ANDREW D
Art Unit
1742
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Canon Inc.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
222 granted / 373 resolved
-5.5% vs TC avg
Strong +23% interview lift
Without
With
+22.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
36 currently pending
Career history
405
Total Applications
across all art units

Statute-Specific Performance

§103
86.5%
+46.5% vs TC avg
§102
10.1%
-29.9% vs TC avg
§112
2.7%
-37.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 373 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-11 in the reply filed on 6/10/2026 is acknowledged. Claims 12-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 6/10/2026. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-11 are rejected under 35 U.S.C. 103 as being unpatentable over Kodama (US 2010/0009287). Regarding claim 1, Kodama discloses a curable composition containing a polymerizable compound (par. 0023 – “polymerizable monomer”), a photopolymerization initiator (par. 0023), and a solvent (par. 0035), wherein the polymerizable compound contains an aromatic compound (par. 0029), the curable composition has a viscosity of 8-50 mPas at 25 C (par. 0083 – falls within the claimed range), in a state which solvent is removed, the curable composition has a viscosity of 30-10000 mPas at 26 C without a solvent (par. 0083); and a content of the solvent is 70-95% of the total composition (par. 0114). It has been held that where the prior art discloses a range that overlaps with or lies inside of the claimed range, a prima facie case of obviousness exists. Accordingly, one of ordinary skill in the art would have found it obvious to have specified that the viscosity of the solvent is as claimed. Regarding claims 2-3, Kodama discloses the subject matter of claim 1, and “the polymerizable compound contains not less than one type of a polymerizable compound” is inherent in meeting “containing a polymerizable compound” (from claim 1); and a boiling point of the compound at normal pressure (interpreted as 1 atm) is not less than 250 C. and a molecular weight is not less than 200 (par. 0116 expresses values much larger than 200, “at least 2000”). Regarding claims 4-6, Kodama discloses the subject matter of claim 1, and “the solvent contains not less than one type of a solvent” is inherent with the presence of “a solvent” (met in claim 1), and a boiling point of the solvent is 70-200 C, or 80-180 C, or 100-160 C (par. 0111) which all at least overlap with the ranges presented in claims 4-6. It has been held that where the prior art discloses a range that overlaps with or lies inside of the claimed range, a prima facie case of obviousness exists. Accordingly, one of ordinary skill in the art would have found it obvious to have specified that the boiling points of the solvent is as claimed. Regarding claims 7-9, Kodama discloses the subject matter of claim 1, and further discloses that the polymerizable compound is a polymer having a polymerizable functional group (par. 0028-0030) which would have some examples where the parameter as defined would be between 2 and 3 (see par. 0058-0081 containing examples of the polymerizable monomer which would contain a polymerizable functional group). Regarding claims 10-11, Kodama discloses the subject matter of claim 1, and further discloses that the solvent is 70-85% of the composition (par. 0111) and that the composition is an inkjet composition (par. 0125). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW D GRAHAM whose telephone number is (469)295-9232. The examiner can normally be reached Monday - Friday 7:30AM-4:00PM (CST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christina Johnson can be reached at (571) 272-1176. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREW D GRAHAM/Primary Examiner, Art Unit 1742
Read full office action

Prosecution Timeline

Nov 09, 2023
Application Filed
Jun 29, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12684696
TRANSFER MOLDING SYSTEMS FOR SEMICONDUCTOR DEVICE PACKAGING
3y 2m to grant Granted Jul 14, 2026
Patent 12673460
Method For Manufacturing Three-Dimensional Shaped Object, And Three-Dimensional Shaping Apparatus
3y 3m to grant Granted Jul 07, 2026
Patent 12654389
METHODS AND SYSTEMS FOR PRINTING BIOLOGICAL MATERIAL
5y 6m to grant Granted Jun 16, 2026
Patent 12654354
METHOD FOR PRODUCING A LIGNOCELLULOSIC COMPOSITE MATERIAL AND COMPOSITE MATERIAL OBTAINED BY THIS METHOD
2y 9m to grant Granted Jun 16, 2026
Patent 12649289
THERMOPLASTIC BRAIDING FOR THE MANUFACTURE OF COMPOSITE ARTICLES
2y 7m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
82%
With Interview (+22.7%)
3y 6m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 373 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month